Blood glucose related adverse drug reaction of antitumor monoclonal antibodies
a retrospective analysis using Vigibase
DOI:
https://doi.org/10.1590/s2175-97902020000118893Keywords:
mAbs, ADR, Hyperglycemia, Vigibase, AntitumorAbstract
On the increasing prevalence of using mAbs (monoclonal antibodies) in cancer therapy and the severe risk of hyperglycemia, we aimed to analyze the main clinical ADRs of mAbs, with a focus on adverse hyperglycemic events associated with currently clinically used mAbs. mAbs as well as target information were selected from Martinadale book and published articles. Drug approving information was collected from each government website, and ADR statistic data were collected from VigibaseR, comparing with Adverse Event Reporting System of US FDA. Top 10 mAbs were classified within listing in total ADR records, ADRs per year, hyperglycemic ADR records. Vigibase data were updated onto 15 Feb 2019. 20 mAbs were analyzed with 263217 ADR reports, wherein 16751 records on Metabolism and nutrition disorders and 1444 records on Glucose metabolism disorders. The geographic, age, gender distributions and annual ADR report numbers were listed respectively. Of the top 10, Rituximab, Bevacizumab and Nivolumab were on the top 3 in total ADR record and hyperglycemic record. Top 3 record results were similar in Vigibase and FDA database. It is of increasing importance for clinicians to be aware of early detection, patient management, or drug selection strategies when using mAbs, particularly within the high glycemic risk-reported mAbs, to improve the efficacy and tolerability of mAbs regiment and optimize patient outcomes.
Downloads
References
Bonamichi-Santos R, Castells M. Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies. Clin Rev Allergy Immunol. 2018;54(3):375-385.
Brunello A, Kapoor R, Extermann M. Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity. Am J ClinOncol. 2011;34(3):292-296.
Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S et al. The prevalence and impact of hyperglycemia and hyperlipidemia in patients with advanced cancer receiving combination treatment with the mammalian target of rapamycin inhibitor temsirolimus and insulin growth factor-receptor antibody cixutumumab.Oncologist. 2015;20(7): 737-741.
Dankner R, Chetrit A, Segal P. Glucose tolerance status and 20 year cancer incidence. Isr Med Assoc J. 2007;9(8): 592-596.
Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene. 2009;28(34): 3009-3021.
Guan M, Zhou YP, Sun JL, Chen SC. Adverse events of monoclonal antibodies used for cancer therapy. Biomed Res Int. 2015;2015:428169.
Gül N, van Egmond M. Antibody-dependent phagocytosis of tumor cells by macrophages: a potent effector mechanism of monoclonal antibody therapy of cancer. Cancer Res. 2015;75(23):5008-5013.
Haluska P, Menefee M, Plimack ER, Rosenberg J, Northfelt D, LaVallee T et al. Phase I dose-escalation study of MEDI- 573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors. Clin Cancer Res. 2014;20(18):4747-4757.
Henricks LM, Schellens JH, Huitema AD, Beijnen JH. The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treat Rev. 2015;41(10):859-867.
Issafras H, Bedinger DH, Corbin JA, Goldfine ID, Bhaskar V, White ML et al. Selective allosteric antibodies to the insulin receptor for the treatment of hyperglycemic and hypoglycemic disorders. J Diabetes Sci Technol. 2014;8(4):865-873.
Kalaivani M, Singh A, Kalaiselvan V. Therapeutic monoclonal antibodies and the need for targeted pharmacovigilance in India. MAbs. 2015;7(1):276-280.
Mehta A, Forero-Torres A. Development and integration of antibody-drug conjugate in non-hodgkin lymphoma. Curr Oncol Rep. 2015;17(9):41.
Mukund S, Shang Y, Clarke HJ, Madjidi A, Corn JE, Kates L et al. Inhibitory mechanism of an allosteric antibody targeting the glucagon receptor. J Biol Chem. 2013;288(50): 36168-36178.
Nicodemus CF. Antibody-based immunotherapy of solid cancers: progress and possibilities. Immunotherapy. 2015;7(8):923-939.
Patel P, Srinivas S. Toxicities of targeted agents in advanced renal cell carcinoma. Curr Clin Pharmacol. 2011;6(3): 181-188. Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/
» https://www.ncbi.nlm.nih.gov/pubmed/
Reidy-Lagunes DL, Vakiani E, Segal MF, Hollywood EM, Tang LH, Solit DB et al. A phase 2 study of the insulin- like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer. 2012;118(19):4795-4800.
Vigibase data. [cited 2019 Feb 15]. Availabe from: Availabe from: http://www.who-umc.org/
Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15(6):361-370.
Yang J, Jia B, Qiao Y, Chen W, Qi X. Variations of blood glucose in cancer patients during chemotherapy. Niger J ClinPract. 2016;19(6):704-708.
Yang JC, Dai YY, Wang LM, Xie YB, Zhou HY, Li GH. Glycemic variation in tumor patients with total parenteral nutrition. Chin Med J (Engl). 2015;128(15):2034-2039.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
